Cordis Receives FDA Clearance for Vascular Stent Systems for Use in SFA
Cordis Corp. has announced it has received FDA clearance for its S.M.A.R.T. CONTROL vascular stent systems for use in the superficial femoral artery and/or the proximal popliteal artery, according to a news release.
Cordis, part of the Johnson & Johnson family of companies, said the S.M.A.R.T. stent is the first stent in the Unites States with both iliac and SFA indications.
"We are very pleased to offer an expanded indication for the S.M.A.R.T. stent," said Shlomi Nachman, worldwide president of Cordis, in the release. "Our goal is to continue to make expanded indications and new products available to our customers so they may bring these innovations to their patients."
Related Articles on FDA Clearances:
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
- Ameritox Joins Progressive Medical's Urine Drug Monitoring Network
- 8 Recent Eye Surgery Center Openings, Mergers & Acquisitions
- Harbor House Rehabilitation and Nursing Center to Open Orthopedic Unit
- Johnson & Johnson Will No Longer Produce Metal-on-Metal Hip Implants
- Spinal Elements Relocates Headquarters to 40,000-Square-Foot Facility